Mark M Smits


Affiliation: VU University Medical Center
Country: The Netherlands


  1. Smits M, Muskiet M, Tushuizen M, Kwa K, Karemaker J, van Raalte D, et al. Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase. Diabetes Res Clin Pract. 2014;106:617-26 pubmed publisher
    ..Based on these data, we hypothesize that in patients with uncomplicated type 2 diabetes, insulin resistance hampers adequate meal-induced sympathetic activation, leading to a decrease in SVR and resulting in a postprandial drop in DBP. ..
  2. Smits M, Muskiet M, Tonneijck L, Kramer M, Diamant M, van Raalte D, et al. GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. Arterioscler Thromb Vasc Biol. 2015;35:1538-43 pubmed publisher
    ..Acute exenatide infusion increases capillary perfusion via nitric oxide-independent pathways in healthy overweight men, suggesting direct actions of this GLP-1RA on microvascular perfusion or interaction with vasoactive factors. ..
  3. Smits M, Tonneijck L, Muskiet M, Hoekstra T, Kramer M, Diamant M, et al. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Arterioscler Thromb Vasc Biol. 2016;36:2125-32 pubmed publisher
    ..Our data suggest that the effects of GLP-1-based therapies on glucose are not mediated through microvascular responses. ..
  4. request reprint
    Smits M, Tonneijck L, Muskiet M, Kramer M, Pouwels P, Pieters van den Bos I, et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia. 2016;59:2588-2593 pubmed
    ..ClinicalTrials.gov NCT01744236 FUNDING : Funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282521 - the SAFEGUARD project. ..
  5. request reprint
    Smits M, Tonneijck L, Muskiet M, Hoekstra T, Kramer M, Diamant M, et al. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;176:77-86 pubmed
    ..In line with pre-clinical data, direct sino-atrial stimulation may be involved. ..
  6. Smits M, Tonneijck L, Muskiet M, Kramer M, Pieters van den Bos I, Vendrik K, et al. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. Diabetes Care. 2017;40:301-308 pubmed publisher
    ..Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected. The long-term clinical consequences of these discrete changes require further study. ..
  7. Smits M, Tonneijck L, Muskiet M, Hoekstra T, Kramer M, Diamant M, et al. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. Diabetes Res Clin Pract. 2017;124:1-10 pubmed publisher
    ..Acute exenatide-infusion prevented the meal-induced decline in diastolic BP, although prolonged liraglutide intervention did not affect postprandial haemodynamics. The meal-induced drop in BP was augmented during sitagliptin-treatment. ..